Literature DB >> 29291347

Absence of Albumin Improves in Vitro Cellular Uptake and Disruption of Poloxamer 407-Based Nanoparticles inside Cancer Cells.

Ana Loureiro1, Jennifer Noro1, Ana S Abreu2, Eugénia Nogueira1, Diana Soares da Costa3,4, Carla Silva1, Artur Cavaco-Paulo1.   

Abstract

Novel nanoparticles based on Poloxamer 407 and vegetable oil were produced by high pressure homogenization. Functionalization of those nanoparticles was made by incorporation of folic acid (FA)-Poloxamer 407 conjugate. These nanoparticles showed suitable characteristics for intravenous therapeutic applications similarly to PEGylated albumin-based nanoparticles, previously described by our research group. Here, we found that the absence of albumin at the interface of Poloxamer 407-based nanoparticles improves the overall process of in vitro cellular uptake and nanoparticle disruption inside cancer cells (folate receptor, FR, positive cells). The results presented here suggest that interfacial composition of those nanoparticles is of paramount importance for drug trafficking inside cancer cells.

Entities:  

Keywords:  cancer therapy; folic acid−Poloxamer 407 conjugate; folic acid−Poloxamer 407 nanoparticles; nanoparticle disruption; specific drug release

Mesh:

Substances:

Year:  2018        PMID: 29291347     DOI: 10.1021/acs.molpharmaceut.7b00893

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  2 in total

Review 1.  A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology.

Authors:  Taiki Miyazawa; Mayuko Itaya; Gregor C Burdeos; Kiyotaka Nakagawa; Teruo Miyazawa
Journal:  Int J Nanomedicine       Date:  2021-06-09

2.  Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.

Authors:  Josué Carvalho; Artur Paiva; Maria Paula Cabral Campello; António Paulo; Jean-Louis Mergny; Gilmar F Salgado; João A Queiroz; Carla Cruz
Journal:  Sci Rep       Date:  2019-05-28       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.